Moshad east Zerbaxa treatment HABP or VABP critical Phase III clinical study reaches major endpoint

recently, the U.SPharmaceutical(Merck and Co) announced that the critical Phase III clinical study (NCT0207757) for the treatment of the antibiotic Zerbaxa (ceftolozane/tazobactam) in hospitals has reached a pre-defined endzerbaxaZerbaxa is a compound antibioticproduct(administered intravenously, consisting of ceftolozane (cephalospora) and tazobactam, a new type of cephalosporinantibiotics, and a beta-neaminease inhibitorZerbaxa was originally developed by antibiotic giant Cubist, who was a key factor in the acquisition of Mercit for $9.5 billion in late 2014in the U.Smarket, Zerbaxa was approved at the end of 2014 and current lysopathy is: (1) for the treatment of complex urinary tract infections (cUTI, including reneusis) ;(2) in adult patients, and is used to treat complex abdominal infections (cII) in adult patients caused by easily transgenic gram-negative bacteria and gram.coma strong competitor to Avycaz
Avycaz, a strong competitor to Zerbaxa in Mersadon, whosedrug(composed of a broad-spectrum cephalosporin ceftazidime (cephalosporine) and a beta-endamidease inhibitor bacavitam (Avibatan)Cephalosporin is a third-generation cephalosporin, an antibiotic product commonly used to treat severe Gram-negative bacterial infections, and avibactam is a new generation of non-beta-lactamia beta-amidase inhibitors that will protect ceftazidime from the breakdown of beta-lactamase produced by these drug-resistant negative bacteriarelated research
a forward-looking, random, double-blind, multicenter, non-effects study conducted in 726 adult patients diagnosed with HABP or VABP for intravenous antibiotic treatment, assessed the efficacy and safety of Zerbaxa relative to Mermgmenan, a wide-spectrum injectable antibiotic that is widely used clinically to treat serious infectionsstudy, Zerbaxa administered at an experimental dose of 3g, Meropinan with 1g, 2 drugs were treated with intravenous infusion sin every 8 hours for 8-14 days, and for copper-green pseudomonas infection for 14 daysdata show that Zerbaxa achieved non-disadvantage compared to controlled drugs in terms of all-cause mortality and clinical cure rates on the 28th day of follow-up after treatmentDetails of the study will be published at a future medicalconferenceBased on this data, Mercadon has planned to submit a new indication application for Zerbaxa to the U.SFood and Drug Administration (
FDA) and the EuropeanDrug(EMA)